Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
HRCT, Blood Draw
Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 101 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Hematuria, Urothelial Carcinoma
Interventions
Cxbladder
Diagnostic Test
Lead sponsor
Pacific Edge Limited
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
10
States / cities
San Diego, California • Bay Pines, Florida • Miami, Florida + 7 more
Conditions
Bladder Cancer, Urinary Bladder Neoplasm, Urologic Neoplasms, Neoplasms, Urinary Bladder Diseases
Interventions
Fiducial marker placement, Multiparametric MRI (mpMRI)
Procedure · Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts
Conditions
Breast Cancer
Interventions
Cardiac Magnetic Resonance Imaging (CMR), Echocardiogram (ECHO)
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Osteosarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Refractory Childhood Malignant Germ Cell Tumor, Refractory Childhood Osteosarcoma, Refractory Childhood Rhabdomyosarcoma, Refractory Childhood Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Wilms Tumor
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Erdafitinib, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
114
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 91 more
Conditions
Prostate Cancer
Interventions
Biopsy
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 90 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Malignant Pleural Effusion, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
carboplatin, docetaxel, gemcitabine hydrochloride, paclitaxel, computed tomography, positron emission tomography, fludeoxyglucose F 18, imaging biomarker analysis
Drug · Procedure · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Seattle, Washington
Conditions
Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage III Follicular Thyroid Cancer, Stage III Papillary Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer
Interventions
sorafenib tosylate, laboratory biomarker analysis, pharmacological study, fludeoxyglucose F 18, positron emission tomography, dynamic contrast-enhanced magnetic resonance imaging
Drug · Other · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Glioblastoma
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History Study of Biomarkers in Pulmonary Arterial Hypertension

NCT01730092
Conditions
Pulmonary Disease, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma, Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Blood Sample, Bone Scan, Computed Tomography, Entinostat, Ipilimumab, Nivolumab, Pharmacogenomic Study, Pharmacological Study, Positron Emission Tomography
Procedure · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
5
States / cities
Duarte, California • New Haven, Connecticut • Baltimore, Maryland + 1 more
Conditions
Chronic Lung Disease, Hematopoietic Cell Transplantation, Graft Versus Host Disease
Interventions
Not listed
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
36 Months and older
Enrollment
375 participants
Timeline
2023 – 2028
U.S. locations
6
States / cities
Stanford, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
Conditions
Cryopyrin-Associated Periodic Syndromes, Amyloidosis
Interventions
124I AT-01
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational

Postoperative Neurocognitive Disorders

NCT04244162
Conditions
Obstructive Sleep Apnea, Neurocognitive Disorders
Interventions
Brain Imaging, Cognitive testing, Blood Biomarkers
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Breast Cancer
Interventions
Diffusion weighted MRI
Device
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Brain Metastases, Neurocognitive Deficit, White Matter Alterations, Radiation Exposure
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma, Stage IV Prostate Adenocarcinoma
Interventions
Computed Tomography, Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Laboratory Biomarker Analysis, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
Andrei Iagaru
Other
Eligibility
19 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Lung Carcinoma, Solitary Pulmonary Nodule, Cigarette Smoking Behavior
Interventions
Computed Tomography, fluorodeoxyglucose F-18, Fluorine F 18 L-glutamate Derivative BAY94-9392, Laboratory Biomarker Analysis, Positron Emission Tomography, Positron Emission Tomography (PET)
Procedure · Radiation · Drug + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
40 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Nashville, Tennessee
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Tumor Imaging, Tumor Tissue Collection, Blood Sample Collection
Diagnostic Test · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,065 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
18
States / cities
Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more
Conditions
Rheumatoid Arthritis
Interventions
Rituximab
Biological
Lead sponsor
Gaylis, Norman B., M.D.
Individual
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Fort Lauderdale, Florida • Hollywood, Florida • Miami, Florida + 2 more
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Resectable Breast Carcinoma
Interventions
Magnetic Resonance Imaging, Mammogram, Ultrasound, Ultrasound-Guided Biopsy, Twinkle marker
Procedure · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 60 Years
Enrollment
463 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
11
States / cities
Birmingham, Alabama • San Diego, California • Torrance, California + 8 more
Completed Phase 2 Interventional Results available

Denosumab and MRI Breast Imaging

NCT02613416
Conditions
Breast Cancer
Interventions
Denosumab
Drug
Lead sponsor
Alison Stopeck
Other
Eligibility
Up to 75 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Stony Brook, New York
Conditions
Very Preterm Maturity of Infant, Very Low Birth Weight Infant
Interventions
Standardized Fortification, Adjustable Fortification
Dietary Supplement
Lead sponsor
Children's National Research Institute
Other
Eligibility
Up to 4 Weeks
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Washington D.C., District of Columbia